Mainz Biomed

Mainz Biomed Interest Coverage

The Interest Coverage Ratio of Mainz Biomed (MYNZ) as of Oct 30, 2026 is -17.51. In the previous year, Interest Coverage Ratio was -32.91 — a change of -46.78% (higher).

Interest Coverage

-17.51

YoY

-46.78%

Last updated:

Interest Coverage Ratio of Mainz Biomed is 2024 -17.51 . Interest Coverage Ratio of Mainz Biomed was 2023 -32.91 . It decreases by -46.78% higher compared to the previous year.

The Mainz Biomed Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2019
-5.76 USD
Jan 1, 2020
-4.26 USD
Jan 1, 2021
-48.62 USD
Jan 1, 2022
-125.92 USD
Jan 1, 2023
-32.91 USD
Jan 1, 2024
-17.51 USD
The Mainz Biomed Interest Coverage history
YEARInterest CoverageYoY
-17.51-46.78%
-32.91-73.86%
-125.92+158.98%
-48.62+1,042.44%
-4.26-26.13%
-5.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mainz Biomed Stock analysis

What does Mainz Biomed do? Mainz Biomed NV generates revenue through its genetic diagnostic testing services segment, offering products like ColoAlert, a stool-based DNA test for colorectal cancer screening, and PancAlert, a stool-based test for pancreatic cancer detection. The company also provides GenoStrip, a platform technology for molecular genetic pathogen detection in environments. Its primary customers include healthcare providers and diagnostic laboratories seeking advanced cancer screening solutions. Mainz Biomed competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc. in the molecular genetics diagnostics market. The firm's product portfolio targets specific cancer types with non-invasive screening methods, focusing on colorectal and pancreatic cancers. ColoAlert and PancAlert are designed for early detection, while GenoStrip serves environmental pathogen monitoring. Mainz Biomed's revenue streams derive from the sale of these diagnostic tests and platform technology to healthcare institutions and laboratories. Mainz Biomed's business model centers on developing and commercializing molecular genetic diagnostic tools, with ColoAlert and PancAlert as key revenue drivers. The company's competitors in the diagnostics sector include Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc., indicating a market focused on innovative cancer screening technologies. Mainz Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mainz Biomed stock

Interest Coverage Ratio of Mainz Biomed is -17.51 in 2024.

Interest Coverage Ratio of Mainz Biomed changed from -32.91 to -17.51, representing a -46.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Mainz Biomed since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Mainz Biomed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mainz Biomed

All Key Metrics — Mainz Biomed